AstriVax

AstriVax

Biotechnology Research

Heverlee, Flemish Region 2,780 followers

Committed to address real-world challenges in vaccinology

About us

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Heverlee, Flemish Region
Type
Privately Held

Locations

Employees at AstriVax

Updates

Similar pages